Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Gregory M. Weinhoff, the Chief Business Officer of Centessa Pharmaceuticals plc (NASDAQ:CNTA), a company currently valued at $2.1 billion, recently executed a series of stock transactions, according to a filing with the Securities and Exchange Commission. According to InvestingPro data, the company maintains a strong balance sheet with more cash than debt, earning a FAIR financial health score. On March 25, 2025, Weinhoff sold 10,000 ordinary shares of Centessa Pharmaceuticals at a weighted average price of $16.3386 per share. This sale, conducted under a Rule 10b5-1 trading plan, amounted to a total of $163,386. The transaction price represents a premium to the current trading price of $14.54, with analysts maintaining a bullish stance and setting price targets between $26 and $36.
In addition to the sale, Weinhoff also exercised options to acquire 10,000 shares at a price of $3.85 per share, totaling $38,500. Following these transactions, Weinhoff’s direct ownership in Centessa Pharmaceuticals stands at 134,021 shares. The ordinary shares may be represented by American Depositary Shares, each equivalent to one ordinary share. For deeper insights into CNTA’s valuation, financial health, and additional ProTips, visit InvestingPro.
In other recent news, Centessa Pharmaceuticals has garnered attention with several significant developments. BMO Capital Markets reiterated its Outperform rating on Centessa, maintaining a price target of $35.00, following the company’s positive fourth quarter 2024 earnings per share (EPS). The firm highlighted the anticipated Phase II results for ORX750, a drug candidate for sleep disorders, expected in 2025, with an 80% probability of success. In parallel, TD Cowen reiterated a Buy rating on Centessa, emphasizing the promising development of ORX750 and its potential game-changing impact in treating narcolepsy and idiopathic hypersomnia.
Additionally, Centessa appointed Dr. Stephen Kanes as its new Chief Medical (TASE:BLWV) Officer. Dr. Kanes brings over 30 years of experience in neuroscience and drug development, aiming to advance Centessa’s pipeline of orexin receptor 2 agonists. Meanwhile, Cowen research firm initiated coverage of Centessa with a Buy rating, expressing optimism about ORX750’s potential to address unmet needs in hypersomnia treatment. The financial community remains focused on Centessa’s progress, particularly the transformative potential of its OX2R agonist portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.